PTEN and neoplasm: When considering tissue-based markers (which require invasive biopsy to complete), a study completed in the PRIAS trial demonstrated that tumor PTEN status is associated with GG upgrading and adverse pathology at prostatectomy, though the study was limited in size and has not been externally validated [28].